Table 2.
Prevalence of TDR From 1997 to 2014 Among 1658 Patients in Central NC
| TDR Category | No. (%) | Common SDRMs | No. (%) |
|---|---|---|---|
| Any TDR | 199 (12.0) | K103N | 97 (5.9) |
| NNRTI | 113 (6.8) | T215Y/F/S/C/D/E/I/V | 37 (2.2) |
| NRTI | 48 (2.9) | M41L | 20 (1.2) |
| PI | 13 (0.8) | G190A | 19 (1.1) |
| NNRTI + NRTI | 11 (0.7) | Y181C | 13 (0.8) |
| NRTI + PI | 6 (0.4) | L90M | 13 (0.8) |
| NNRTI + NRTI + PI | 5 (0.3) | M46I/L | 11 (0.7) |
| NNRTI + PI | 3 (0.2) | L210W | 10 (0.6) |
Abbreviations: NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SDRM, surveillance drug resistance mutation; TDR, transmitted drug resistance.